Punicalagin Attenuates LPS-Induced Inflammation and ROS Production in Microglia by Inhibiting the MAPK/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation

Jung Lo; Ching-Chih Liu; Yueh-Shan Li; Po-Yen Lee; Po-Len Liu; Pei-Chang Wu; Tzu-Chieh Lin; Chi-Shuo Chen; Chien-Chih Chiu; Yu-Hung Lai; Yo-Chen Chang; Hsin-En Wu; Yuan-Ru Chen; Yu-Kai Huang; Shu-Pin Huang; Shu-Chi Wang; Chia-Yang Li

doi:10.2147/JIR.S372773

Punicalagin Attenuates LPS-Induced Inflammation and ROS Production in Microglia by Inhibiting the MAPK/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation

J Inflamm Res. 2022 Sep 15:15:5347-5359. doi: 10.2147/JIR.S372773. eCollection 2022.

Authors

Jung Lo^{1

2}, Ching-Chih Liu^{3

4}, Yueh-Shan Li³, Po-Yen Lee^{3

5}, Po-Len Liu⁶, Pei-Chang Wu^{1

2}, Tzu-Chieh Lin⁷, Chi-Shuo Chen⁸, Chien-Chih Chiu⁹, Yu-Hung Lai^{3

5

10}, Yo-Chen Chang^{3

5

10}, Hsin-En Wu³, Yuan-Ru Chen³, Yu-Kai Huang^{3

11}, Shu-Pin Huang^{1

12

13

14}, Shu-Chi Wang^{15

16

17}, Chia-Yang Li^{3

16

17

18}

Affiliations

¹ Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
² Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan.
³ Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
⁴ Department of Ophthalmology, Chi Mei Medical Center, Tainan, 71004, Taiwan.
⁵ Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
⁶ Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
⁷ Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
⁸ Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, 30013, Taiwan.
⁹ Department of Biotechnology, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
¹⁰ Department of Ophthalmology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
¹¹ Department of Neurosurgery, Kaohsiung Medical University Hospital, Kaohsiung, 80708, Taiwan.
¹² Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
¹³ Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
¹⁴ Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
¹⁵ Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
¹⁶ Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
¹⁷ Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, 80756, Taiwan.
¹⁸ Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung, 91201, Taiwan.

Abstract

Purpose: Neurodegenerative diseases are associated with neuroinflammation along with activation of microglia and oxidative stress, but currently lack effective treatments. Punicalagin is a natural bio-sourced product that exhibits anti-inflammatory effects on several chronic diseases; however, the anti-inflammatory and anti-oxidative effects on microglia have not been well examined. This study aimed to investigate the effects of punicalagin on LPS-induced inflammatory responses, NLRP3 inflammasome activation, and the production of ROS using murine microglia BV2 cells.

Methods: BV2 cells were pre-treated with punicalagin following LPS treatment to induce inflammation. The secretion of NO and PGE₂ was analyzed by Griess reagent and ELISA respectively, while the expressions of iNOS, COX-2, STAT3, ERK, JNK, and p38 were analyzed using Western blotting, the production of IL-6 was measured by ELISA, and the activity of NF-κB was detected using promoter reporter assay. To examine whether punicalagin affects NLRP3 inflammasome activation, BV2 cells were stimulated with LPS and then treated with ATP or nigericin. The secretion of IL-1β was measured by ELISA. The expressions of NLRP3 inflammasome-related proteins and phospho IκBα/IκBα were analyzed using Western blotting. The production of intracellular and mitochondrial ROS was analyzed by flow cytometry.

Results: Our results showed that punicalagin attenuated inflammation with reduction of pro-inflammatory mediators and cytokines including iNOS, COX-2, IL-1β, and reduction of IL-6 led to inhibition of STAT3 phosphorylation by LPS-induced BV2 cells. Punicalagin also suppressed the ERK, JNK, and p38 phosphorylation, attenuated NF-κB activity, inhibited the activation of the NLRP3 inflammasome, and reduced the production of intracellular and mitochondrial ROS by LPS-induced BV2 cells.

Conclusion: Our results demonstrated that punicalagin attenuated LPS-induced inflammation through suppressing the expression of iNOS and COX-2, inhibited the activation of MAPK/NF-κB signaling pathway and NLRP3 inflammasome, and reduced the production of ROS in microglia, suggesting that punicalagin might have the potential in treating neurodegenerative diseases.

Keywords: MAPK; NF-κB; NLRP3 inflammasome; microglia; punicalagin.